Chapter 11

Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy

Hutteman M1, van der Vorst JR1, Mieog JSD, Bonsing BA, Hartgrink HH, Kuppen PJK, Löwik CWGM, Frangioni JV, van de Velde CJH, Vahrmeijer AL

1 Shared first authorship

ABSTRACT

Background

Intraoperative visualization of pancreatic tumors has the potential to improve radical resection rates. Intraoperative visualization of the common bile duct and bile duct anastomoses could be of added value. In this study, we explored the use of indocyanine green (ICG) for these applications, and attempted to optimize injection timing and dose.

Methods

Eight patients undergoing a pancreaticoduodenectomy were injected intravenously with 5 or 10 mg ICG. During and after injection, the pancreas, tumor, common bile duct, and surrounding organs were imaged in real-time using the Mini-FLARE™ near-infrared (NIR) imaging system.

Results

No clear tumor-to-pancreas contrast was observed, except for incidental contrast in one patient. The common bile duct was clearly visualized using NIR fluorescence, within 10 minutes after injection, with a maximal contrast between 30 to 90 min after injection. Patency of biliary anastomoses could be visualized due to biliary excretion of ICG.

Conclusion

No useful tumor demarcation could be visualized in pancreatic cancer patients after intravenous injection of ICG. However, the common bile duct and biliary anastomoses were clearly visualized during the observation period. Therefore, these imaging strategies could be beneficial during biliary surgery in cases where the surgical anatomy is aberrant or difficult to identify.
INTRODUCTION

Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States, with an incidence of approximately 38,000 cases and an estimated 34,000 deaths. The overall 5-year survival rate is very low (<5%).\(^1\) Approximately 10% to 15% of patients are eligible for surgical resection, which is presently the only potentially curative treatment option. Even after curative resection, the reported 5-year survival rates are disappointing and vary from 10% to 17%.\(^2\) Several factors, such as tumor size, lymph node status, tumor grade, and blood vessel invasion are correlated with prognosis. Involvement of tumor margins is an important prognostic factor, as reported survival for R0 (radical) resections (20.3 months) is twice that of R1 resections (10.3 months).\(^6\) For preoperative staging and determination of resectability, the imaging procedure of choice is a multiphase, multidetector helical computed tomography (CT) with intravenous administration of a contrast agent combined with an endoscopic ultrasonography.\(^7\)

During pancreatic surgery, assessment of the extent of the pancreatic tumor is made based on visual inspection and palpation, sometimes in conjunction with intraoperative ultrasonography.\(^8\) Intraoperative tumor identification remains challenging, partly because the surrounding pancreatic tissue is frequently inflamed. Local recurrence rates of 72% to 86% are reported,\(^10\) which in part could be caused by inadequate intraoperative evaluation of the location and extent of the tumor.

Near-infrared (NIR) fluorescence imaging is a promising technique to facilitate intraoperative, real-time, visual information.\(^13\) In order to detect tumors using NIR fluorescence, contrast agents that target tumor-specific characteristics can be used to selectively label tumor cells.\(^16\) Novel NIR fluorescent agents have been developed that target tumor-specific cell surface markers,\(^16\) enzymatic activity,\(^17\) or increased glucose metabolism.\(^22\) However, these tumor-specific agents are not yet available for clinical use. The only NIR fluorescent contrast agents currently available, methylene blue and indocyanine green (ICG), are not tumor-specific. However, the enhanced permeability and retention (EPR) effect can potentially be used to obtain accumulation of non-targeted contrast agents in tumors.\(^23\) Due to newly formed, more porous blood vessels, molecules can passively accumulate into the surrounding tissue. Furthermore, poorly developed lymphatics in the tumor result in an increased retention. Previous studies showed breast carcinomas and liver tumors could be identified noninvasively with NIR fluorescence using ICG based on the EPR effect.\(^25\) The aim of our study was to assess the applicability of NIR fluorescence imaging using ICG to provide a clear tumor-to-background contrast in oncologic pancreatic surgery.

Because ICG is almost exclusively excreted into the bile, it can also be used for intraoperative NIR fluorescence exploration of the biliary anatomy.\(^29\) This can be useful in patients with a difficult laparoscopic cholecystectomy, due to an aberrant biliary anatomy or an acute cholecystitis, for example. Furthermore, ICG can potentially
be used to assess anastomosis patency in patients undergoing bile duct reconstruction. This is a well-suited setting to study both biliary anatomy and anastomosis patency intraoperatively, as the common bile duct can be visualized for a long time during pancreaticoduodenectomy.

**MATERIALS AND METHODS**

**Intraoperative Near-Infrared Imaging System (Mini-FLARE™)**

Intraoperative imaging was performed using the hand-held Fluorescence-Assisted Resection and Exploration (Mini-FLARE™) image-guided surgery system as described in Chapter 6. This system consists of two wavelength isolated light sources: a “white” light source, generating 26,600 lx of 400-650 nm light and a NIR light source, generating 7.7 mW/cm² of 760 nm light. Color video and NIR fluorescence images are simultaneously acquired and displayed in real-time using custom optics and software that separate the color video and NIR fluorescence images. A pseudo-colored (lime green) merged image of the color video and NIR fluorescence images is also displayed. The imaging head is attached to a flexible gooseneck arm, which permits positioning of the imaging head virtually anywhere over the surgical field, even at extreme angles. For intraoperative use, the imaging head and imaging system pole stand are wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, USA).

**Preparation and Administration of Indocyanine Green**

ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) and resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 mM) stock solution. Of this stock solution 2 or 4 mL, corresponding with doses of 5 or 10 mg, was administered.

**Clinical Trial**

The study was approved by the Local Medical Ethics Committee of the Leiden University Medical Center and was performed in accordance with the ethical standards of the Helsinki Declaration of 1975. A total of 8 consecutive patients with suspected ampullary or pancreatic head carcinoma planned to undergo curative resection were included. All patients provided informed consent. Exclusion criteria included pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine green. The surgical technique used in our center implies a standard pancreaticoduodenectomy with resection of peripancreatic tissues and lymph nodes. Following resection, reconstruction is performed with pancreaticojejunostomy, choledochojejunostomy,
Pancreatic cancer and bile duct imaging and pylorojejunostomy for pylorus preserving pancreaticoduodenectomy or a gastrojejunostomy as part of Whipple's procedure. After opening the omental bursa, performing the Kocher maneuver, and exploration of the hepatoduodenal ligament, the pancreatic tumor was fully exposed. The Mini-FLARE imaging system was positioned 30 centimeters above the surgical field. Next, 4 patients were intravenously administrated 5 mg ICG diluted in 2 mL sterile water as a bolus and 4 patients were intravenously administrated 10 mg ICG diluted in 4 mL sterile water as a bolus. All operating room lights, with the exception of the white light and NIR light of the Mini-FLARE imaging system, were dimmed. The NIR fluorescence measurements of the pancreatic tumor, pancreas, duodenum, stomach, liver, gall bladder, and common bile duct were recorded at the time of injection (T=0), 45 seconds and 3-, 10-, 30-, 60-, 90-, 120-, 180- min post-injection. At each measurement, camera exposure times were set appropriately to prevent the NIR fluorescence signal from reaching saturation. Bile duct imaging ended at 90 min because the bile duct was resected at this time as part of the pancreaticoduodenectomy. Furthermore, imaging of the choledochojejunostomy was performed to assess leakage and patency. Fluorescent intensity of these structures was quantified using the custom Mini-FLARE software. To calculate tumor-to-pancreas ratios, tumor and healthy pancreas regions of interest were manually drawn, guided by palpation. Signal-to-background ratios (SBR) for the common bile duct were manually drawn, and a background region of interest was drawn on direct surrounding tissue.

Statistical Analysis

For statistical analysis and graph design, GraphPad Prism Software (Version 5.01, La Jolla, USA) and SPSS (Version 17.0, Chicago, USA) were used. All data were reported as mean ± standard deviation or median and range. To compare the signal-to-background ratios between the two concentration groups, T-tests were used. Repeated-measures ANOVAs were used to test differences between time points. All statistical tests were two-tailed and $P < 0.05$ was considered significant.

RESULTS

Patient and tumor characteristics are listed in Table 1. Eight patients undergoing surgery for a suspected ampullary or pancreatic head carcinoma were included in the study. In one patient, the common bile duct was cut several minutes after ICG administration and therefore measurements beyond 3 min were excluded from the analysis. Four patients underwent a complete Whipple procedure, three patients underwent a pylorus preserving pancreaticoduodenectomy, and one patient had an irresectable tumor, resulting in a biopsy without further resection.
<table>
<thead>
<tr>
<th>Pt</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Weight (kg)</th>
<th>Length (cm)</th>
<th>BMI</th>
<th>AF (U/L)</th>
<th>gGT (U/L)</th>
<th>ASAT (U/L)</th>
<th>ALAT (U/L)</th>
<th>Tumor size (cm)</th>
<th>Tumor location</th>
<th>Surgery</th>
<th>T N M R Vasc inv Perin inv</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>39</td>
<td>M</td>
<td>90</td>
<td>186</td>
<td>26</td>
<td>261</td>
<td>86</td>
<td>92</td>
<td>155</td>
<td>n/a</td>
<td>Head</td>
<td>Bypass</td>
<td>3 + - n/a n/a n/a</td>
<td>Poorly diff. adenoca.</td>
</tr>
<tr>
<td>2</td>
<td>76</td>
<td>V</td>
<td>64</td>
<td>164</td>
<td>24</td>
<td>97</td>
<td>72</td>
<td>21</td>
<td>16</td>
<td>4.7</td>
<td>Ampulla</td>
<td>Whipple</td>
<td>3 - - R0 - +</td>
<td>Poorly diff. adenoca.</td>
</tr>
<tr>
<td>3</td>
<td>45</td>
<td>M</td>
<td>65</td>
<td>179</td>
<td>20</td>
<td>118</td>
<td>274</td>
<td>20</td>
<td>19</td>
<td>4</td>
<td>Head</td>
<td>PPPD</td>
<td>3 + - R1 - +</td>
<td>Well diff. adenoca.</td>
</tr>
<tr>
<td>4</td>
<td>32</td>
<td>M</td>
<td>88</td>
<td>188</td>
<td>25</td>
<td>114</td>
<td>66</td>
<td>48</td>
<td>78</td>
<td>-</td>
<td>Whipple</td>
<td>-</td>
<td>-</td>
<td>No malignancy</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>V</td>
<td>75</td>
<td>169</td>
<td>26</td>
<td>72</td>
<td>46</td>
<td>69</td>
<td>40</td>
<td>6</td>
<td>Head</td>
<td>Whipple</td>
<td>2 + - R1 - -</td>
<td>Adenoca.</td>
</tr>
<tr>
<td>6</td>
<td>61</td>
<td>V</td>
<td>73</td>
<td>176</td>
<td>24</td>
<td>674</td>
<td>1472</td>
<td>280</td>
<td>292</td>
<td>1.7</td>
<td>Head</td>
<td>PPPD</td>
<td>3 + - R0 - +</td>
<td>Adenoca.</td>
</tr>
<tr>
<td>7</td>
<td>46</td>
<td>V</td>
<td>89</td>
<td>170</td>
<td>31</td>
<td>42</td>
<td>11</td>
<td>59</td>
<td>39</td>
<td>1.8</td>
<td>Head</td>
<td>Whipple</td>
<td>1 + - R1 - -</td>
<td>Neuroendocrine</td>
</tr>
<tr>
<td>8</td>
<td>62</td>
<td>M</td>
<td>68</td>
<td>180</td>
<td>21</td>
<td>71</td>
<td>64</td>
<td>21</td>
<td>23</td>
<td>2.3</td>
<td>Duodenum</td>
<td>PPPD</td>
<td>- - R0 - -</td>
<td>Adenomatous polyp</td>
</tr>
</tbody>
</table>

AF, alkaline phosphatase; gGT, gamma-glutamyltransferase; ASAT, aspartate transaminase; ALAT, alanine transaminase; Vasc inv, vascular invasion; Perin inv, perineural invasion; n/a, not available due to irresectable tumor; PPPD, pylorus-preserving pancreaticoduodenectomy.
Tumor Imaging

Directly after injection, superficial arterial flow of ICG was identified by NIR fluorescence on the surface of the pancreas followed by venous drainage. In the 5-mg patient group (N = 4), a mean tumor-to-pancreas ratio of 0.89 ± 0.25 was observed. In the 10-mg patient group (N = 4), a mean tumor-to-pancreas ratio of 1.22 ± 0.39 was observed (Figure 1a). Time had no significant effect on tumor-to-pancreas ratio (P = 0.899). Tumor-to-pancreas ratios were significantly higher in the 10-mg group, when compared to 5-mg group (P = 0.002). In one patient (patient 5, 10-mg dose group), a clear NIR fluorescent hotspot was observed on the pancreas (Figure 1b). Histological analyses confirmed that the signal corresponded to tumor tissue surrounding the pancreatic duct. Other than this incidental finding, no contrast was observed.

**Figure 1. Tumor-to-Pancreas Contrast using NIR Fluorescence and ICG:** A. Tumor-to-pancreas ratios (mean ± SD) of the pancreatic tumors over time, per dose group. B. Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of intraoperative imaging of the pancreas. In this example, clear contrast (arrow) is shown between pancreatic tumor and normal pancreatic tissue (P), 20 min after administration of 10 mg of ICG. However, this was an incidental finding in one patient. The duodenum is marked with the letter D.

Imaging of the Common Bile Duct using NIR Fluorescence

Within 10 min after administration of ICG, the common bile duct, cystic duct, and common hepatic duct could clearly be identified by NIR fluorescence (Figure 2a and b) in all patients. The NIR fluorescence signal of the liver outshined the left and
right hepatic ducts and therefore prevented a clear visualization. The fluorescent signal of the bile ducts lasted until 90 min postinjection, at which point the bile duct was resected, along with the head of the pancreas and the duodenum, as part of the pancreaticoduodenectomy. No difference was observed between the 5-mg and 10-mg groups ($P = 0.849$). Time significantly influenced signal-to-background ratio ($P = 0.002$). An optimum was found between 30 and 90 min postinjection, with a maximum mean signal-to-background ratio of $6.24 \pm 1.32$ at 60 min postinjection. After completion of the choledochojejunostomy, anastomotic patency could be confirmed by visualizing the NIR fluorescence signal passing the anastomosis into the jejunum (Figure 2c).

**Figure 2. Intraoperative Imaging of the Common Bile Duct using NIR Fluorescence and ICG:** A. Signal-to-background ratios (mean ± SD) of the common bile duct over time, per dose group. Signal-to-background ratios (SBR) for the common bile duct were calculated. A background region-of-interest was drawn on direct surrounding tissue. B. Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of intraoperative imaging of the common bile duct in a patient who underwent a cholecystectomy during previous surgery, 30 min after administration of 5 mg ICG. A clear contrast is shown between common bile duct (arrow) and surrounding tissue. C. Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of a choledochojejunostomy (arrow), 30 min after completion of the anastomosis. NIR fluorescence signal of excreted ICG is visualized intraluminally in the jejunum, indicating anastomotic patency and absence of leakage.
**Biodistribution of ICG**

The NIR fluorescence signal of the pancreas, stomach, liver, duodenum and common bile duct was measured at fixed time intervals (Figure 3). As reported in preclinical studies, within the first 2 min vascular signal (an arterial phase followed by a venous phase) could be visualized. The pancreas, stomach and duodenum showed comparable washout patterns. As ICG is cleared by the liver, the liver and common bile duct exhibited high levels of NIR fluorescence, indicating hepatic uptake and clearance in bile.

**DISCUSSION**

The first objective of this study was to exploit the EPR effect to induce retention of the non-targeted probe ICG in pancreatic tumors. However, in all but one patient, no useful intraoperative tumor-to-pancreas ratios in pancreatic cancer patients were observed using NIR fluorescence and ICG. In one patient, a clear hotspot was observed on the pancreas, which corresponded with the resected adenocarcinoma. No specific pathological characteristics were observed that could account for this phenomenon. Several factors might explain the observed lack of contrast in all other patients. Healthy pancreas tissue showed a relatively high uptake of ICG, whereas tumor tissue showed similar uptake. As washout of NIR fluorescence signal was comparable in both healthy pancreas tissue and tumor tissue, no EPR effect could be visualized. This is possibly the result of different tumor biology of pancreatic cancer when compared to breast cancer, in which the EPR effect has been observed in previous studies. Several earlier studies reported a lower perfusion of tumor tissue in comparison with healthy pancreas tissue, which might decrease availability of ICG for a potential EPR effect of the tumor. Furthermore, previous studies that reported an EPR effect of ICG in breast tumors used detection methods (laser scanning or optical tomography), that
may detect lower concentrations of ICG but require post-processing, and are therefore not applicable for real-time intraoperative imaging.\textsuperscript{26, 27}

Novel NIR fluorescent probes are being developed to increase signal penetration depth and decrease background uptake. For multiple applications within cancer surgery, it is imperative to design improved tumor targeting probes. Tumor targeting can be accomplished by conjugating a fluorophore to a targeting ligand such as antibodies or peptides, for example.\textsuperscript{16, 19, 21, 22} It is expected that several of those tumor targeted probes will be available for first-in-human trials within the coming years.

The second objective of this study was to evaluate the biodistribution of ICG and its clearance by the liver into the bile. Patients undergoing a pancreaticoduodenectomy are well suited for this study, as the bile ducts and abdominal organs can be studied for a relatively long time. As stated before, iatrogenic common bile duct injury occurs in patients undergoing cholecystectomy. A non-invasive imaging modality that can visualize the common bile duct intraoperatively could potentially reduce the incidence of common bile duct injury in these patients. For example, this technique can help the surgeon identify vital structures during difficult laparoscopic cholecystectomies in patients with acute cholecystitis or aberrant biliary anatomy. This technique could potentially prevent the need to convert to an open procedure.

In this study, the common bile duct was identified using NIR fluorescence imaging after ICG administration in all patients. This is in concordance with preclinical data, described by Matsui et al.\textsuperscript{30} and in clinical studies of patients undergoing cholecystectomy.\textsuperscript{29, 31} A useful contrast between the common bile duct and surrounding tissue was observed starting at 10 min postinjection. The optimal timing of ICG administration prior to imaging lies between 30 and 90 min. In this interval, mean SBRs of 5 to 6 were observed. Ideally, background fluorescence levels of all surrounding organs should be minimal. In this study, the liver signal remained high throughout the imaging interval. Although this did not prevent a contrast being observed between common bile duct and surrounding tissues, future studies should focus on optimal timing to minimize background fluorescence, especially when studying the liver. Indeed, in a separate study, in which patients with colorectal liver metastases were injected intravenously with 10 mg ICG at 24 hours prior to liver surgery, liver fluorescence decreased to background levels, while bile duct imaging was still possible. However, compared to the fluorescent intensity observed in the present study, the bile duct signal was significantly decreased by 88 \% (van der Vorst et al., manuscript in preparation). Therefore, novel NIR fluorescent agents should be developed that are excreted into bile, with minimal liver uptake, thereby reducing background fluorescence and increasing the ability to visualize bile ducts. In contrast to most other imaging systems, the Mini-FLARE imaging system used in this study can display the NIR fluorescence signal in relation to the surgical anatomy, by simultaneously displaying color video and NIR fluorescence. This feature is of added
benefit in performing true image-guided surgery. The Mini-FLARE can only be used during open surgery. However, most cholecystectomies are performed by laparoscopy. In order to enable intraoperative NIR fluorescence imaging during laparoscopic surgery, laparoscopic camera systems are currently being developed and tested.30, 31, 35 Furthermore, as with all novel techniques, large clinical studies are necessary to prove the added value of NIR fluorescence imaging in patients undergoing a cholecystectomy. These trials can use the data presented in this study to select the optimal time of imaging after ICG administration.

This study showed that no useful tumor demarcation could be visualized in pancreatic cancer patients using intraoperative NIR fluorescence imaging after ICG administration. Furthermore, our study showed the ability to visualize the common bile duct after ICG administration and demonstrated the influence of time on signal-to-background ratio. Moreover, patency of the jejunal-biliary anastomosis could be visualized. For a translation to clinical practice, larger trials should be executed. This is dependent on broad availability of commercial intraoperative NIR fluorescence imaging systems. When these imaging systems become available for use in the clinic in the coming years, the true value of this technique can be assessed.

ACKNOWLEDGEMENTS

We thank Lindsey Gendall for editing. This work was supported in part by the Nuts Ohra Fund, the Foundation “Maurits and Anna de Kock”, and NIH grant #R01-CA-115296.
REFERENCES
